The race to discover an artificial melanin source that is compatible with people who are melanin deficient continues on.
A study done by The National Eye Institute (NEI) indicates that the drug Nitisinone may increase Melanin production in people who are melanin deficient, specifically people with oculocutaneous albinism type 1B (OCA-1B).
Nitisinone is a drug used to treat hereditary tyrosinemia type 1, which is “a genetic disorder characterized by disruptions in the multistep process that breaks down the amino acid tyrosine, a building block of most proteins.” This disorder significantly affects a person’s ability to produce melanin. Albinos and Caucasians suffer from this genetic disorder. The NEI study suggest that Nitisinone may increase melanin production in Albinos, but fail to also include it could increase melanin in Caucasians as well.
Having sufficient levels of melanin is crucial to maintaining a healthy homeostasis on planet earth. This is perhaps why it’s been reported that Caucasians as a collective have a lower birth rate then death rate, they are one of the lowest melanin producing species alive. This is what I believe inspires all of the recent research and experiments with melanin – melanin cyborg implants, melanin conductivity research, and melanin injections. It is important for those who are melanin deficient to become melanin sufficient in order to maintain genetic survival. Nitisinone is just one of the many ways scientists are trying to ‘even the score’ between people who have melanin and the people who don’t.